MAIA Biotechnology, Inc. (MAIA) - 10-K Summary
Business Context and Reporting Period
Company: MAIA Biotechnology, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: MAIA is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Its lead asset, THIO (generic name: ateganosine), is a telomere-targeting agent designed to prime the immune system for subsequent checkpoint inhibitor therapy. The company is currently conducting Phase 2 clinical trials (THIO-101) for Non-Small Cell Lung Cancer (NSCLC) and plans to initiate a Phase 3 pivotal trial (THIO-104) in 2025.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(23,254,656) | $(19,772,905) |
| Operating Expenses | $16,957,210 | $20,182,381 |
| Cash and Cash Equivalents (Year End) | $9,601,298 | $7,150,695 |
| Working Capital | $6,322,441 | $2,626,899 |
| Accumulated Deficit | $(87,234,833) | $(63,980,177) |
| Stockholders' Equity | $3,634,636 | $477,511 |
Note: The 2024 Net Loss includes a non-cash loss of approximately $6.68 million related to the change in fair value of warrant liabilities.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by 16% ($3.2 million) compared to 2023. This reduction was driven by lower payroll expenses (due to headcount reductions and reversal of accrued bonuses) and decreased stock-based compensation, partially offset by a $2.05 million increase in clinical trial expenses for the THIO-101 study.
- Other Income/Expense: Net other expense increased significantly to $6.3 million in 2024 from net other income of $0.4 million in 2023. This was primarily due to a $6.88 million loss on the change in fair value of warrant liabilities.
- Liquidity: Cash reserves increased by approximately $2.45 million to $9.6 million, supported by net cash provided by financing activities of $18.2 million (including private placements and At-The-Market offerings).
- Capital Structure: The company raised significant capital in 2024 through multiple private placements and an At-The-Market (ATM) offering, resulting in the issuance of approximately 8.4 million new shares and warrants.
Guidance, Outlook, and Risks
Clinical Outlook:
- THIO-101 (Phase 2 NSCLC): Enrollment for the primary cohort was completed in February 2024. An expansion arm was initiated in Q1 2025 to evaluate efficacy in third-line NSCLC patients. Recent data (as of Jan 2025) showed a median overall survival of 16.9 months in the third-line setting.
- THIO-104 (Phase 3): Planned initiation in 2025. This pivotal trial will compare THIO + checkpoint inhibitor vs. chemotherapy in third-line NSCLC patients.
- Regulatory: The FDA granted Rare Pediatric Disease Designation (RPDD) for THIO in pediatric-type diffuse high-grade gliomas (PDHGG) in December 2024, potentially qualifying the company for a Priority Review Voucher upon approval.
Going Concern Warning: The independent registered public accounting firm (Grant Thornton LLP) has expressed substantial doubt about the company's ability to continue as a going concern. The company has incurred recurring losses, negative cash flows from operations, and an accumulated deficit of $87.2 million. Continued operations depend on the ability to raise additional equity or debt financing.
Key Risks:
- Funding: Failure to secure additional capital could force the company to delay, limit, or terminate product development.
- Clinical Uncertainty: Results from preclinical and early clinical trials may not predict success in later-stage trials or regulatory approval.
- Competition: Intense competition from established pharmaceutical companies in the oncology space.
- Intellectual Property: Reliance on licensed patents from the University of Texas Southwestern (UTSW); termination of these licenses would halt development.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance against the projected burn rate to determine the immediate timeline for the next capital raise.
- Warrant Liability Volatility: Review the impact of stock price fluctuations on the fair value of warrant liabilities, which significantly impacts reported net loss.
- Clinical Data Validation: Scrutinize the interim data from the THIO-101 trial (specifically the 16.9-month median OS) and the statistical robustness of the sample size.
- Dilution Risk: Assess the potential dilution from outstanding options (~9.8 million), warrants (~6.7 million), and the remaining capacity under the ATM offering ($30 million).
- License Agreements: Confirm compliance with milestone and royalty obligations under the UTSW license agreements to avoid termination risks.